Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.

Autor: Fontanella C; Medical Oncology, ULSS1 Dolomiti - Veneto, Ospedale San Martino, Belluno, Italy., Giorgi CA; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Russo S; Department of Oncology, ASU FC University Hospital, Udine, Italy., Angelini S; Medical Oncology Unit, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy., Nicolardi L; Medical Oncology, Ospedali Riuniti Padova Sud 'Immacolata concezione', Piove di Sacco (PD), Italy., Giarratano T; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Frezzini S; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Pestrin M; Medical Oncology, Azienda Sanitaria Universitaria Giuliano Isontina, Gorizia, Italy., Palleschi D; Medical Oncology Unit, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy., Bolzonello S; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, PN, Italy., Parolin V; Section of Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, Italy., Haspinger ER; Medical Oncology, Azienda Ospedaliera dell'Alto Adige, Merano Hospital, Merano, BZ, Italy., De Rossi C; Medical Oncology, ULSS3 Serenissima, Ospedale dell'Angelo, Mestre Venezia, Italy., Greco F; Department of Oncology, 'Mater Salutis' Hospital, ULSS9, Verona, Italy., Gerratana L; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, PN, Italy. Electronic address: gerratana.lorenzo@spes.uniud.it.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Dec; Vol. 180, pp. 103848. Date of Electronic Publication: 2022 Oct 17.
DOI: 10.1016/j.critrevonc.2022.103848
Abstrakt: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are now a backbone of treatment for hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. CDK4/6i plus ET is more effective than ET alone in this setting; however, the risk of grade 3-4 adverse events also increases. Approved agents in this class have similar efficacies, but important differences due to their structural and pharmacological properties. We review biomarkers and discuss determinants to inform a rational approach to therapy choice when selecting the most appropriate ET and CDK4/6i partners. We also identify subgroups that may benefit from specific ET-CDK4/6i combinations and discuss strategies to overcome resistance. This personalized approach aims to minimize treatment-related toxicities that may affect patient QoL and compliance, and ultimately therapy efficacy.
Competing Interests: Conflict of interest LG reports Consulting or Advisory Role from Eli Lilly and Novartis, outside the submitted work. All other authors declare no potential conflict of interest.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: